Kodiak Sciences Surges 178% After Both Eye Drugs Hit in Phase 3 DAYBREAK

Zenkuda and tabirafusp-ted both matched Eylea on vision in wet AMD, with 54% of Zenkuda patients reaching 24-week dosing — sending the stock from its $3.26 graveyard to $89.92 and setting up a fourth-quarter filing.

Sources

Sources & evidence

What “Source checked” means

Kodiak Sciences closed up 178% at $89.92 on Monday after both of its experimental eye drugs met the primary endpoint in the pivotal DAYBREAK trial in wet age-related macular degeneration — a result that positions the precommercial biotech for a three-indication filing in the fourth quarter and completes one of biotech's most dramatic comebacks: the stock traded at $3.26 in July 2023 after the company abandoned the same drug.

Both drugs hit — and the p-values are tiny

In DAYBREAK, a 675-patient, three-arm study, Zenkuda (tarcocimab tedromer) and tabirafusp-ted both demonstrated non-inferiority to aflibercept — Regeneron's Eylea — in best-corrected visual acuity at one year. Zenkuda's p-value was 0.0007; tabirafusp-ted's was 0.0036 on vision and under 0.0001 on the anatomical key secondary. The trial randomized patients 1:1:1 to the two Kodiak drugs or aflibercept, quadruple-masked, according to the clinicaltrials.gov registry.

The 54% number that moved the stock

The number the market seized on was durability: 54% of Zenkuda patients reached 24-week dosing intervals at year one — under what the company calls strict treat-to-dryness criteria, meaning any detectable retinal fluid on OCT triggered retreatment. Zenkuda is an anti-VEGF antibody-biopolymer conjugate with a claimed mean ocular half-life of about 20 days, roughly three times approved anti-VEGF therapies, designed for flexible dosing from one month to six.

A clean safety sheet, against history

Safety, the ghost of Kodiak's past, came back clean: zero intraocular inflammation and 0.5% cataract adverse events for Zenkuda, versus 0.9% cataract with aflibercept; tabirafusp-ted showed 0.4% inflammation and no cataract signal. That matters because inflammation and cataract imbalance killed the drug's first incarnation.

From $3.26: the redemption arc

The first incarnation died loudly. In February 2022, KSI-301 failed the DAZZLE wet-AMD study and the stock fell nearly 80% to $10.55. In July 2023, after twin GLEAM/GLIMMER diabetic-macular-edema failures with a 19%-versus-9% cataract imbalance, Kodiak abandoned tarcocimab entirely; shares fell by more than half to $3.26 on a $382 million market capitalization. What followed was a slow rebuild: a positive GLOW1 readout in late 2023, GLOW2 in March 2026 — 62.5% of patients with a two-step disease-severity improvement versus 3.3% on sham — and now DAYBREAK, the fifth positive Phase 3. Monday's close values the company at about $5.6 billion.

The honest caveats

The caveats are real. The aflibercept arm was dosed per label — standard 2 mg every eight weeks — not on a durability-optimized schedule, so the 24-week claim reflects regimen design as much as molecule. The topline disclosed no absolute letter gains and no non-inferiority margin; only p-values. Goldman Sachs, which resumed coverage at Neutral days before the readout with analyst Andrea Newkirk arguing positive results were ‘unlikely to meaningfully move shares,’ was proven wrong on the move — but her durable critique stands: tabirafusp-ted was tested on an eight-week schedule, and ‘matching Eylea on this timeline offers little value’ in a market moving to extended-interval drugs like Eylea HD and Vabysmo. Citi's Geoff Meacham added that cross-trial comparisons are imperfect and real-world durability unproven. And the balance sheet is thin: $125.9 million in cash at June 30, down from $209.9 million at year-end, with a formal going-concern warning and a $65.6 million quarterly loss.

What comes next

What comes next is a three-indication biologics license application in the fourth quarter of 2026 — wet AMD, diabetic retinopathy, and retinal vein occlusion — built on five positive Phase 3 studies, plus a December readout for KSI-101 in macular edema. Regeneron fell 3.8% on Monday; the $15 billion global retinal-disease market, by Kodiak's own estimate, just got a new contender. What remains unknown: the full visual-acuity data, whether regulators accept a single three-indication filing, and how the durability holds outside a trial protocol.

Sources & evidence

Source checked6 sources · 6 figures

Figure receipts

Every figure in this article, with the source it came from.

  • $89.92 KOD Monday close

    USD per share · As of Sept. 29, 2026

  • 177.96 Monday gain

    % · As of Sept. 29, 2026

  • 38,463,100 Monday volume

    shares · As of Sept. 29, 2026

  • 54 Zenkuda 24-week durability

    % of patients · As of Sept. 29, 2026

  • $125.9M Cash and equivalents (June 30)

    As of Sept. 29, 2026

  • $15B Global retinal vascular disease market

    USD billions (company estimate) · As of Sept. 29, 2026

All dates 2026. DAYBREAK topline announced Monday September 28; market figures are Monday's confirmed close. Financial figures are from the Q2 2026 10-Q (June 30). biologics license application timing is company guidance.

TickerGrove house illustration for healthcare coverage: a double helix

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories